This bill creates new coverage requirements and related statutory changes. For health plans issued or renewed on or after January 1, 2027, and for managed care organizations beginning January 1, 2027, the bill requires coverage of at least one nonopioid legend drug for the treatment or management of pain without prescription drug utilization management such as prior authorization or step therapy. The bill adds new sections to chapter 48.43 RCW and to chapter 74.09 RCW, reenacts and amends RCW 41.05.017, and amends RCW 48.43.400 to incorporate definitions used elsewhere in the act. The bill defines "nonopioid drug" as an FDA‑approved drug or biological product that produces analgesia without acting on opioid receptors and adopts the existing statutory meanings of "prior authorization" and "step therapy protocol" from RCW 48.43.400. It directs the authority responsible for fee‑for‑service programs and managed care under chapter 74.09 RCW to assure those programs comply with the managed care coverage requirement. It also directs the department to develop and publish by January 1, 2027, an educational pamphlet on nonopioid alternatives for pain, including available alternatives and their advantages and disadvantages. Several details are not provided in the extracted text. The new section number added to chapter 48.43 RCW is not stated, the statutory identities of "the authority" and "the department" are not specified, the specific nonopioid drugs that must be covered are not listed, the pamphlet's contents beyond the two required topics are not given, and the substance of the many referenced RCW provisions that are reenacted or applied is not included.

If enacted, starting January 1, 2027 most Washington health plans, the managed care organizations that contract with the state, and any health care benefit managers they use must cover at least one FDA‑approved nonopioid pain drug without requiring prior authorization or step therapy. Insurers and benefit managers will need to change their drug coverage rules and administrative processes to allow immediate access to at least one nonopioid analgesic, which is likely to raise pharmacy spending in some cases and require operational work to remove utilization controls for that drug. The state health authority must ensure fee‑for‑service programs and managed care comply, and a state department must create and post an educational pamphlet by the same date explaining nonopioid options and their pros and cons, which will require staff time. Important details are missing here — the bill does not list which specific nonopioid drug(s) must be covered or identify the named “authority” and “department,” so insurers and the state will have discretion and some uncertainty in implementing and enforcing the requirement.